MedTrace Logo

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

NCT01251978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-10-19

Study results available
· View outcomes & findings →

Summary

Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

Conditions

  • Choroidal Melanoma

Interventions

DRUG

Ranibizumab 2 mg

intravitreal injections of ranibizumab once a month, times 3.

DRUG

0.5 mg Ranibizumab

6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • New England Retina Associates

    lead OTHER

Principal Investigators

  • Peter E Liggett, MD · New England Retina Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-07-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251978 on ClinicalTrials.gov